Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Why was Remicade prescribed? (arthritis, crohn's disease, etc.)

If Demyelination was diagnosed while taking Remicade, please describe diagnosis:

Was Lymphoma diagnosed after taking Remicade?

Was Tuberculosis (TB) diagnosed after taking Remicade?

If yes, was Tuberculosis ever diagnosed before Remicade?

Were the following side effects a problem while taking Remicade?

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Remicade Side Effects Lawsuits | Side Effects: Blood Abnormalities, Blood Disorders, Abnormal Bleeding, Infections

Remicade Side Effects Could Result In Blood Disorders Lawsuits

Remicade | Lawsuits, Lawyers | Side Effects: Blood Abnormalities, Blood Disorders, Abnormal Bleeding, Infections

Patients taking Remicade (Generic:Infliximab) for rheumatoid arthritis suffered a type of cancer, lymphoma, at three times the rate of the general public, manufacturer Centocor warned. Centocor, a subsidiary of Johnson & Johnson, said the lymphoma incidence rate was six times higher among all patients who took the monoclonal antibody in completed clinical trials.

Remicade is manufactured by Centocor and distributed by Johnson & Johnson and is used to treat rheumatoid arthritis and Crohn's disease. The FDA has been told of 580 adverse reaction reports among 509,000 worldwide patients, said Craig Buchholz, a Centocor spokesman. Forty-four reports were most worrisome because they involved significant blood disorders. At least 12 patients taking Remicade in combination with other drugs died worldwide.

The company's Aug. 11 warning letter to doctors said patients receiving Remicade suffered reductions in their red and white blood cell, granulocyte and platelet counts, leaving them more vulnerable to abnormal bleeding and infections. In rare instances, patients suffered central nervous system disorders, including confusing immune system responses that swelled, and then decayed, blood vessels.

Physicians Warned Exercise Caution With Remicade

Centocor warned physicians to exercise caution when treating patients with histories of significant blood abnormalities with Remicade. Patients with persistent fevers should seek immediate medical attention.

Remicade (Infliximab), an immune-suppressing drug used to treat rheumatoid arthritis and Crohn's disease, is reported to be responsible for 70 reported cases of tuberculosis (TB) among US patients. The cases, at least four of which were fatal, were reported to the Food and Drug Administration between 1998 and May of this year. Researchers who reviewed the cases say that the immune-system protein infliximab suppresses called tumor necrosis factor alpha (TNF-alpha) appears to be key in controlling TB infection.

Around 150,000 people worldwide have received Infliximab infusions since the drug's approval in 1998. Pennsylvania-based Centocor, which announced it was changing the drug's prescribing information to address the TB concerns. The revised labeling states that patients should be tested and treated for inactive, or latent, TB prior to Infliximab therapy. Latent TB refers to a chronic, but symptom less and noncontiguous, infection. Such TB infections are prevalent throughout the world because in most people, the immune system is able to suppress TB bacteria.

Up to 15 million Americans are estimated to have latent TB infections. When the immune system is suppressed as it is in patients on infliximab latent TB can become active. Active TB usually attacks the lungs, causing symptoms such as a severe cough, chest pain and weight loss. It is spread through the air from person to person.

Legal Help For Victims Affected By Remicade

If you or a loved one took Remicade and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


RemicadeRSS Feed

Legionella, Listeria Infections Added to Black Box Warning for TNFa Blockers

Sep 8, 2011 | Parker Waichman LLP
Patients treated with Remicade, Enbrel, Humira, Cimzia and Simponi are at an increased risk of developing Listeria or Legionella infections.  Such drugs, known as Tumor Necrosis Factor-alpha (TNFa) blockers, are immunosuppressive drugs, and it was already known that such medications increased a patient’s risk of serious infections.In a Drug Safety Communication issued yesterday, the U.S. Food & Drug Administration (FDA) announced that information regarding Legionella and Listeria...

FDA Releases More Humira, Enbrel, Remicade Info

Sep 1, 2009 | Parker Waichman LLP
Federal regulators have released  more information regarding cancers associated with drugs like Humira, Enbrel, and Remicade.  Last month, the Food & Drug Administration  (FDA) had mandated that the Black Box  Warnings on these drugs - known as TNF blockers -   highlight their possible  association with lymphoma and other cancers in children and teens.In a  supplementary "Question and Answer" document released yesterday, the FDA provided more...

Simponi Carries Risk of Possibly Fatal Fungal Infections

May 29, 2009 | Parker Waichman LLP
Simponi, a new rheumatoid arthritis drug, can cause severe and potentially fatal fungal infections, according to a new warning released yesterday by the Food & Drug Administration (FDA). Because of this risk, the agency said that when  making a decision to use Simponi, doctors must balance the potential benefits with the potential risks of therapy based upon a patient’s individual need.Simponi is one of a class of drugs known as TNF-alpha blockers.  Such medications work by...

Humira, Kineret, Remicade May Raise the Risk of Developing Shingles

Feb 18, 2009 | Parker Waichman LLP
Shingles seems to be one of the adverse reactions to rheumatoid arthritis sufferers taking Humira, Kineret, and Remicade.  WebMD Health News reported that these drugs, in the TNF-alpha blocker class, nearly doubled the risk of shingles—herpes zoster—in a German study involving 5,040 patient participants.Humira, Kineret, and Remicade each increased the risk of developing shingles by 80 percent according to Anja Strangfeld, MD from the German Rheumatism Research Center in Berlin,...

Humira, Cimzia, Enbrel and Remicade to Bear Stronger Infection Warnings

Sep 4, 2008 | Parker Waichman LLP
Federal regulators have ordered the makers of Humira, Cimzia, Enbrel, and Remicade to strengthen the existing warnings about opportunistic fungal infections linked to the drugs.  At least 45 people are known to have died from such infections.  The Food & Drug Administration (FDA) ordered the new labeling under authority it was granted with the passage of the Food and Drug Administration Amendments Act of 2007.Humira, Cimzia, Enbrel and Remicade are known as tumor necrosis factor...

More Remicade News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo